Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3836MR)

This product GTTS-WQ3836MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3836MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13917MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ14987MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ7917MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ4456MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ148MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6115MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ7951MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ4403MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW